‘This could be transformative’: Surgeon performs first US implant of heart valve still under FDA review

Jennifer Romano, MD, MS, a surgeon with at C.S. Mott Children’s Hospital

Jennifer Romano, MD, MS, a heart surgeon with at C.S. Mott Children’s Hospital, during a procedure. Image courtesy of Siani Johnson.

The size-adjustable pulmonary valve was originally developed by Autus Valve Technologies, which Edwards Lifesciences acquired for $128.9 million. The device was designed to grow with pediatric patients as they age. Clinicians can expand it as necessary with a minimally invasive balloon procedure. 

Medtronic invests up to $80M in medtech company Pi-Cardia with a potential buyout on the table

Pi-Cardia ShortCut TAVR device. According to Pi-Cardia, ShortCut is the first medical device of its kind; interventional cardiologists use it to split valve leaflets in patients who have been recommended for valve-in-valve TAVR and face a heightened coronary obstruction risk.

The ShortCut device. Image courtesy of Pi-Cardia. 

Less than a year after investing heavily in Minnesota-based Anteris Technologies, Medtronic has announced a new strategic investment in Pi-Cardia. The TAVR technology at the heart of this investment is Pi-Cardia's FDA-approved ShortCut device.